Also known as Carbex, Eldepryl, Stilline, Centrapryl, Vivapryl, Zelapar, Atapryl, Emsam, and Anipryl
Selegiline (Anipryl, L-deprenyl, Eldepryl, Emsam, Zelapar) is a drug used for the treatment of early-stage Parkinson's disease, depression and senile dementia. In normal clinical doses it is a selective irreversible MAO-B inhibitor. However, in larger doses it loses its specificity and also inhibits MAO-A. Dietary restrictions are common for MAOI treatments, but special dietary restrictions for lower doses have been found to be unnecessary, and dietary restrictions appear to be unnecessary at standard doses when selegiline is taken as Emsam, the transdermal patch form, as no adverse events due to diet have ever been reported with Emsam. The drug was discovered by Jozsef Knoll et al. in Hungary. Selegiline belongs to a class of drugs called phenethylamines. Selegiline is a levomethamphetamine derivative with a propargyl group attached to the nitrogen atom.Source: Wikipedia
Estimated Total Cost: $120.38 for an average of 28 days supply
Patients are most commonly prescribed selegiline to treat parkinson disease, depression, problems with movement, and abnormal involuntary movements.
Patients taking selegiline most commonly experience side effects like nausea, headache, and pain.